Novo Ups Obesity Ante With $800M+ Deep Apple Pact for Oral, Non-Incretin Drugs

For $812 million, Novo Nordisk will enlist Deep Apple to discover and develop a non-incretin therapy for obesity, months after the Danish pharma’s amylin efforts underwhelmed investors.